KLTO
HEALTHCAREKlotho Neurosciences Inc Com
—PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving KLTO Today?
No stock-specific AI insight has been generated for KLTO yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$57M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding108.1M
KLTO News
20 articles- Greenland Mines Engages WSP Denmark to Launch Comprehensive Environmental Baseline Program at Skaergaard Mining SiteYahoo Finance·Mar 19, 2026
- Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRMLYahoo Finance·Mar 12, 2026
- Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026Yahoo Finance·Mar 9, 2026
- Klotho Neurosciences Expands Into Mining With Greenland Mines DealYahoo Finance·Mar 5, 2026
- KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDORYahoo Finance·Mar 4, 2026
- Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)Yahoo Finance·Feb 24, 2026
- Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene SequenceYahoo Finance·Feb 18, 2026
- Klotho Neurosciences to Present at the Biotech Showcase 2026Yahoo Finance·Jan 8, 2026
- Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' AwardYahoo Finance·Nov 7, 2025
- Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in BostonYahoo Finance·Oct 16, 2025
- Klotho Neurosciences Announces Expiration of Letter of IntentYahoo Finance·Oct 7, 2025
- Klotho to acquire Turn Biotechnologies’ assetsPharmaceutical-technology·Oct 1, 2025
- Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma PartnershipYahoo Finance·Sep 30, 2025
- Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific SeminarYahoo Finance·Sep 8, 2025
- Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease MarketYahoo Finance·Aug 18, 2025
- Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform TechnologyYahoo Finance·Aug 12, 2025
- UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyYahoo Finance·Jul 26, 2025
- Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyYahoo Finance·Jul 24, 2025
- Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy AssetsYahoo Finance·Jul 22, 2025
- Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity RulesYahoo Finance·Jul 16, 2025
All 20 articles loaded
Price Data
Open—
Previous Close—
Day High—
Day Low—
52 Week High$2.45
52 Week Low$0.12
Fundamentals
Market Cap$57M
P/E Ratio—
EPS$-0.30
Dividend Yield—
Dividend / Share—
ROE-2.0%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding108.1M
About Klotho Neurosciences Inc Com
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. The company is headquartered in Omaha, Nebraska.
Listed September 17, 2024
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—